Popular terms

Sleep Disorders topics
Sleep Disorder
Sleep Disorders
Narcolepsy
Schizophrenia
Antagonist
Pyrazole Derivatives
Movement Disorder
Movement Disorders
Eating Disorder
Eating Disorders
Neurological
Pharmaceutically Acceptable Salt
Intracranial
Opiate Withdrawal
Growth Hormone

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Sleep Disorders patents



      

This page is updated frequently with new Sleep Disorders-related patent applications.




Date/App# patent app List of recent Sleep Disorders-related patents
04/07/16
20160095908 
Botulinum toxin for primary disorders of mood and affect using neurotransmitter cns imaging studies
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety, and sleep disorders and cns disorders comprising the administration of a neurotoxin.. .
Botulinum Toxin Research Associates, Inc.


03/24/16
20160083418 
19-nor neuroactive steroids and methods of use thereof
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to formula (i): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus..
Sage Therapeutics, Inc.


03/24/16
20160083417 
19-nor c3, 3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
Provided herein are 19-nor c3,3-disubstituted steroids of formula (i): and pharmaceutically acceptable salts thereof; wherein, , r1, r2, r3a, r3b, r4a, and r4b are as defined herein, and a is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus..
Sage Therapeutics, Inc.


03/17/16
20160075660 
Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia).
Arena Pharmaceuticals, Inc.


03/17/16
20160075656 
Quinoline amide m1 receptor positive allosteric modulators
The present invention is directed to quinoline amide compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositious comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
Merck Sharp & Dohme Corp.


03/10/16
20160068563 
19-nor neuroactive steroids and methods of use thereof
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to formula (i): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus..

03/10/16
20160067216 
Composition of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
The present invention relates to certain compositions of a 5-ht2a serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like.
Arena Pharmaceuticals


03/03/16
20160058862 
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into gbl.
Jazz Pharmaceuticals, Inc.


03/03/16
20160058737 
Imidazolidinedione derivatives
The invention provides a compound of formula (ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of kv3.1 and/or kv3.2, and in the treatment of diseases or disorders where a modulator of kv3.1 and/or kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy..
Autifony Therapeutics Limited


03/03/16
20160058720 
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (ghb). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus..
Jazz Pharmaceuticals Ireland Limited


02/25/16
20160052913 

Substituted benzimidazoles as nociceptin receptor modulators


The invention provides modulators of the nociceptin receptor (nop), including both agonists and antagonists. A compound of the invention can be a selective modulator of nop with respect to the μ- and κ-opioid receptors (mop and kop), thus providing a therapeutic method for the treatment of conditions wherein selective nop modulation is medically indicated and mop or kop modulation may be less desirable.
The Scripps Research Institute


02/25/16
20160051643 

Botulinum toxin and the treatment of primary disorders of mood and affect


The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and cns disorders comprising the administration of a neurotoxin.. .
Botulinum Toxin Research Associates, Inc.


02/04/16
20160030425 

Methods and compositions for sleep disorders and other disorders


Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-ht2a, sert and/or dopamine d2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or parkinson's disease or any combinations..
Intra-cellular Therapies, Inc.


02/04/16
20160030383 

Low-dose doxepin for treatment of sleep disorders in elderly patients


Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle.
Pernix Sleep, Inc.


01/28/16
20160024082 

P2x7 modulators


The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv


01/21/16
20160016962 

P2x7 modulators


The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv


01/14/16
20160009644 

Potent and selective inhibitors of monoamine transporters; making; and use thereof


Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (da), serotonin (5-ht), and/or norepinephrine (ne) reuptake via their respective transporters, dat, sert and net.
The United States Of America, As Represented By Th Secretary, Department Of Health And Human Service


01/14/16
20160008608 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

01/14/16
20160008360 

Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors


Alkyl-piperazine-phenyl 4 (3h)-quinazolinones compounds of general formula (i) below are provided that are pharmacologically active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, including loss of sexual desire, inhibition of sexual desire and absence of sexual desire, among other disorders associated with these receptors..
Ache International (bvi) Ltd.


01/07/16
20160002250 

Polymorphs and salts of a compound


Disclosed are novel crystalline polymorphic forms of 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2h)-one and salts thereof, methods of preparing the crystalline polymorphic forms and salts thereof, pharmaceutical compositions comprising the crystalline polymorphic forms and salts thereof, and methods of treating cns disorders, eating disorders, obesity, compulsive gambling, sexual disorders, narcolepsy, sleep disorders, diabetes, metabolic syndrome, schizophrenia, schizo-affective conditions, huntington's disease, bipolar disorders, dystonic conditions and tardive dyskinesia, or for use in smoking cessation treatment in a patient using the crystalline polymorphic forms and salts thereof.. .
Forum Pharmaceuticals Inc.


12/10/15
20150352038 

A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder


A dosage form for oral administration, via the mucous membranes, of an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder, the active principle being lipophilic or amphiphilic and being in a dissolved state that is stable and complete in a hydro-alcoholic solution having 35% to 70% by weight of ethanol and 30% to 65% by weight of water, generating nanostructures of the active principle under consideration within the hydro-alcoholic solution, thereby enabling the active principle to cross the blood-brain barrier, the active principle being in base and/or salt form and belonging to the chemical families of sleep inducers or modulators of lipophilic or amphiphilic type and of molecular weight that is less than 1000 da, the active principle being selected from the families of imidazopyridines, including zolpidem, the family of cyclopyrrolones, including eszopiclone, the family of pyrazolopyrimidines, including zaleplon, the family of benzodiazepines, including midazolam and brotizolam, the family of h1-antihistamine sedatives, including doxylamine and cyproheptadine, and/or the family of melatonin and melatonin agonists, including melatonin, ramelteon, and agomelatine, the volume of the hydro-alcoholic solution being less than or equal to 2 ml, and the active principle being present at a dosage that is less than or equal to 8 mg, all of the active principle being absorbed in transmucosal manner via the mucous membranes of the floor of the oral cavity, in particular via the gums/cheeks, via the gum area, via the cheeks, or under the tongue.. .

12/03/15
20150342779 

Devices, the treatment of sleep apnea


A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth.
Lumen Devices Llc


11/26/15
20150335659 

New uses of ganaxolone


Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects.
Wisconsin Alumni Research Foundation


11/26/15
20150335507 

Systems, methods, and devices for treatment of sleep disorders


A sleep apparatus, such as a mattress, comprises a head support surface sized to support a person's head, and a torso support surface sized to support a person's torso. The head support surface is generally laterally sloped moving from a first side toward a second side of the mattress, and the torso support surface is generally laterally sloped moving from the first side toward the second side.
Hill-rom Services, Inc.


10/29/15
20150306391 

Deep brain stimulation for sleep disorders


In some examples, a medical device delivers electrical stimulation to the external portion of the globus pallidus of a brain of a patient in order to treat a sleep impairment of the patient. In some examples, the electrical stimulation may be delivered via one or more electrodes implanted in the gpe of the brain.
Medtronic, Inc.


10/15/15
20150291654 

3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof


Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to formula (i) and (iii): where r1, r2, r3, r3′, r4, r6a, r6a, r11a, and r11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (tbi), stress, and epilepsy..

10/15/15
20150290177 

Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof


The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the ph of saliva to a ph greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form.

10/08/15
20150283019 

Tactile transducer treatment system


A tactile transducer treatment system includes a foundation that is configured to support a mattress. At least one tactile transducer device is mounted to the foundation.

09/17/15
20150259414 

Anti-acth antibodies and use thereof


The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.


09/03/15
20150246140 

Compositions and methods for modulating sleep and wakefulness


In some aspects, the invention relates to methods of treating conditions associated with sleep disorders, comprising administering an agent that modulates the activity of a neuropeptide receptor or a neuropeptide receptor ligand. In some aspects, the invention relates to methods of screening agents that modulate the activity of a neuropeptide receptor in an organism, optionally using cells or organisms comprising a genetic modification that affects a neuropeptide signaling pathway.
California Institute Of Technology


08/27/15
20150239832 

Analogs and prodrugs of loop diuretics, including bumetanide, furosemide and piretanide; compositions and methods of use


Novel analogs and prodrugs of the loop diuretics bumetanide, furosemide and piretanide are described. Pharmaceutical compositions containing loop diuretic analogs and prodrugs are also described.
Neuro Pro Therapeutics, Inc.


08/27/15
20150238347 

Dental sleep appliance


A dental oral appliance for use with patients who suffer with sleep disorders, to reduce or eliminate snoring or obstructive sleep apnea and to open the airway for a sleeping patient. Retention for the appliance is provided by an occlusal coverge, or wire clasps, on the upper or lower teeth.

07/16/15
20150196257 

Systems and methods for physiological signal enhancement and biometric extraction using non-invasive optical sensors


A system and method for signal processing to remove unwanted noise components including: (i) wavelength-independent motion artifacts such as tissue, bone and skin effects, and (ii) wavelength-dependent motion artifact/noise components such as venous blood pulsation and movement due to various sources including muscle pump, respiratory pump and physical perturbation. Disclosed are methods, analytics, and their uses for reliable perfusion monitoring, arterial oxygen saturation monitoring, heart rate monitoring during daily activities and in hospital settings and for extraction of physiological parameters such as respiration information, hemodynamic parameters, venous capacity, and fluid responsiveness.
The Board Of Regents, The University Of Texas System


06/25/15
20150175573 

Heteroaromatic compounds and their use as dopamine d1 ligands


And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mci, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

06/18/15
20150164945 

Preparation for improving the action of receptors


This preparation is advantageously applied in patients suffering from parkinson's disease, huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and adhd.. .

05/21/15
20150141669 

Prodrug of fluorine-containing amino acid


Provided are a fluorine-containing amino acid prodrug represented by general formula (i) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, alzheimer's disease, huntington's chorea, parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases..
Taisho Pharmaceutical Co., Ltd.


05/21/15
20150141444 

N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators


The present invention is directed to n-methyl tetrahydroquinoline compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
Merck Sharp & Dohme Corp.


05/14/15
20150133675 

Pde10 inhibitors and related compositions and methods


Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.

05/14/15
20150132283 

Botulinum toxin and the treatment of primary disorders of mood and affect


The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and cns disorders comprising the administration of a neurotoxin.. .

05/07/15
20150125548 

Combination nutritional and nutraceutical products


The present invention is directed to nutritional and nutraceutical compositions which comprise novel mixtures of two or more indole-based dietary supplements such as l-tryptophan and melatonin, together with selected minerals and vitamins that stimulate tryptophan metabolism in the direction of serotonin and melatonin, and to their use in a preferred embodiment of the invention in a readily ingested beverage form, optionally combined with a range of other natural ingredients designed to improve the health and state of mind of human subjects. Alternative dosage forms, such as tablets for oral dosing, and dosage forms for buccal and sublingual administration, including thin films, are also incorporated in the present invention.
Requis Pharmaceuticals Inc.


04/30/15
20150119381 

Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders


The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient..
Pfizer Inc.


04/09/15
20150099761 

Modulators of fatty acid amide hydrolase


4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a faah modulator. 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
Janssen Pharmaceutica Nv


03/26/15
20150087894 

Method and device for monitoring and treating sleep disorders and sleep-related conditions


Methods and apparatus for monitoring, diagnosing, and treating sleep disorders such as sleep terrors are provided, which may include any number of features. One feature is an apparatus configured to partially awaken a user to treat a sleep disorder.

03/12/15
20150073052 

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy


Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into gbl.
Jazz Pharmaceuticals, Inc.


03/05/15
20150065498 

N-linked lactam m1 receptor positive allosteric modulators


The present invention is directed to n-linked lactam compounds of general formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

02/26/15
20150057443 

Cycloalkyl amine compounds


Wherein ring a is c3-c6 cycloalkyl, optionally substituted with one or more c1-c3 alkyl, and r5 is ors2, in which rs2 is h or c1-c6 alkyl, or r5 and r6, together with the carbon atom to which they are attached, form c═o, for use in treating cns disorders, including movement disorders, depressive disorders, sleep disorders, cognitive dysfunctions, obesity, sexual dysfunction and substance abuse.. .

02/19/15
20150051239 

Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists


This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes.
Abbvie Bahamas Limited


02/05/15
20150037309 

Preparation for improving the action of receptors


This preparation is advantageously applied in patients suffering from parkinson's disease, huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and adhd.. .

01/29/15
20150031713 

Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators


Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

01/15/15
20150018377 

Imidazolidinedione derivatives


The invention provides a compound of formula (ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of kv3.1 and/or kv3.2, and in the treatment of diseases or disorders where a modulator of kv3.1 and/or kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy..
Autifony Therapeutics Limited


01/08/15
20150007830 

Oral appliances and methods of use


Provided herein are oral appliances and methods of using oral appliances for treatment of sleep disorders and conditions.. .
Zst Holdings, Inc.


12/11/14
20140364395 

Pyranyl aryl methyl benzoquinolinone m1 receptor positive allosteric modulators


Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

11/27/14
20140345060 

Systems, methods, and devices for the treatment of sleep disorders


A sleep apparatus, such as a mattress for example, is provided in one embodiment. The apparatus comprises a head support surface sized to support a person's head, and a torso support surface sized to support a person's torso.

11/20/14
20140343279 

Process for the preparation of histamine h3 receptor modulators


The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.. .

11/13/14
20140336199 

Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors


Which are pharmacologicaly active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors..

10/30/14
20140323423 

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders...


Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

10/16/14
20140309227 

Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use


The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (i) wherein ring a, rq, -l-, r1, n, r2, and r3 are as defined herein. The compounds of the invention are useful as non-competitive mglur2 antagonists, or mglur2 negative allosteric modulators (nams), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mglur2-nam receptor is involved, such as alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

10/09/14
20140303372 

Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists


And derivatives thereof, which are antagonists of 5-ht6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes..

10/09/14
20140303179 

Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors


This invention is related to the alkyl-piperazine-phenyl 4 (3h)-quinazolinones general formula (i) compounds, pharmacologicaly active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors..

09/04/14
20140249090 

Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders


The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide s receptor (npsr), of the receptor tgr23 and/or of vasopressin receptor-related receptor 1 (vrr1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition.

08/14/14
20140228581 

Pde10 inhibitors and related compositions and methods


Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.

08/14/14
20140228562 

Treatment of sleep disorders


The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.. .

08/14/14
20140225736 

System and detecting sleep disorders


An apparatus for detecting sleep disorders, such as obstructive sleep apnea, includes a housing insertable into an ear canal of a subject. A sensor disposed within the housing measures a position of the subject's head relative to an axis of gravity.

08/07/14
20140221395 

Deuterium-enriched alkyl sulfonamides and uses thereof


The present invention is concerned with deuterium-enriched sulfonamides of formula 1, their pharmaceutically acceptable salts and methods of use thereof for the treatment of anxiety disorders including, general anxiety disorder (gad), panic disorder (pd), post-traumatic stress disorder (ptsd), social phobia (sp), health anxiety (hypochondriasis), depression, major depressive disorders, unipolar depression, bipolar i depression disorder, bipolar ii depression disorder, treatment-resistant depression, single episodic and recurrent major depressive disorders, depression in the medically ill, attention deficit hyperactivity disorder (adhd), attention deficit disorder (add), obsessive-compulsive disorder (ocd), obsessive-compulsive personality disorder (ocpd), autism spectrum disorder (asd), schizophrenia, psychosis, epilepsy, seizures, hot flashes due to menopause, age-related macular degeneration (amd), premature ejaculation, male erectile dysfunction, sexual dysfunction, obesity, eating disorders, bulimia nervosa, anorexia nervosa, angina, migraine, pain, nociception, sleep disorders, insomnia, fibromyalgia, alcohol withdrawal, autism, rett's syndrome, cyclothymic disorder, neural injury, neurodegenerative diseases, parkinson's disease, parkinson's disease psychosis, huntington disease, alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, alzheimer's disease, schizophrenia, psychosis, depression, pain or discomfort associated with surgery and pain or discomfort associated with medical illness.. .

08/07/14
20140221322 

Heteroaryl substituted urea modulators of fatty acid amide hydrolase


Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..

07/24/14
20140207220 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

07/17/14
20140200222 

N-linked quinolineamide m1 receptor positive allosteric modulators


The present invention is directed to n-linked quinoline amide compounds of general formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

07/03/14
20140186457 

Honey composition with l-alanyl-l-glutamine


The present invention relates to compositions includes honey and l-alanyl-l-glutamine, pharmaceutical compositions thereof and a combined product comprising honey and l-alanyl-l-glutamine for a simultaneous, separate or sequential use in therapy. The composition, pharmaceutical composition and combined product have particular utility in improving sleep and treating sleep disorders such as insomnia or sleep apnoea..

06/19/14
20140171506 

Gamma-hydroxybutyrate compositions and their use for the treatment of disorders


Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (ghb). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus..

06/19/14
20140171505 

Gamma-hydroxybutyrate compositions and their use for the treatment of disorders


Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (ghb). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus..

05/29/14
20140148720 

Method and device(s) for diagnosis and/or treatment of sleep apnea and related disorders


Method and device for diagnosing and/or treating sleep apnea and related sleep disorders, such as snoring and respiratory effort-related arousals, includes an inflatable implement which is applied to the external surface of the chest and/or abdomen (vest). Pressure is caused to rise to a predetermined positive value.

05/29/14
20140148440 

Heterocyclyl compounds as histamine h3 receptor ligands


The present invention relates to heterocyclyl compounds of formula (i), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts.

04/17/14
20140107084 

Ultra low dose doxepin and methods of using the same to treat sleep disorders


The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.. .

03/06/14
20140066504 

Analogs and prodrugs of bumetanide; compositions and methods of use


Novel analogs and prodrugs of the loop diuretic bumetanide are described. Pharmaceutical compositions containing bumetanide analogs and prodrugs are also described.

03/06/14
20140066412 

Heteroaryl substituted urea modulators of fatty acid amide hydrolase


Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..

02/20/14
20140051750 

Low-dose doxepin for treatment of sleep disorders in elderly patients


Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle.

02/20/14
20140050783 

Methods and compositions for sleep disorders and other disorders


Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-ht2a, sert and/or dopamine d2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or parkinson's disease or any combinations..

02/13/14
20140045800 

Tetracyclic inhibitors of fatty acid amide hydrolase


Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis)..

02/13/14
20140045755 

Methods for treating sleep disorders by cholecystokinin (cck) receptor b antagonists


The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (cck) receptor antagonists..

02/06/14
20140038951 

Pde10 inhibitors and related compositions and methods


Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.

01/09/14
20140011775 

Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists


This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes.

01/02/14
20140005182 

Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators


Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

12/12/13
20130331610 

Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates


The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (i) wherein r, r1, x and y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (i) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation.

12/12/13
20130331571 

Glycine transporter-inhibiting substances


The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.. .

12/12/13
20130331401 

Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates


The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (i) wherein r, r1, x and y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (i) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation.

12/12/13
20130331396 

Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase


Certain piperazinyl and piperidinyl urea compounds are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity.

12/05/13
20130324788 

Method and treatment of sleep disorders


A system for therapy may include a mask (200) for a patient having a frame, cushion, forehead support and a light (100). The mask is connectable to a respiratory treatment apparatus, such as a flow generator, to receive breathable gas for a respiratory therapy.

11/28/13
20130312768 

Apparatus and methods for the treatment of sleep apnea


A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus comprises an elongate member with a middle portion, a first fixation element and a second fixation element.

11/07/13
20130296993 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

11/07/13
20130296413 

N-desmethyl-doxepin and methods of using the same to treat sleep disorders


Desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.. .

10/10/13
20130267595 

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy


Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into gbl.

09/19/13
20130245022 

Heteroaryl-substituted urea modulators of fatty acid amide hydrolase


Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..

08/22/13
20130217729 

Piperidine sulphonamide derivatives


Wherein ar1, ar2, r1, r2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula i are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases..

08/22/13
20130217700 

Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto


Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia).

08/15/13
20130210856 

Compositions and methods for treating sleep disorders


The present invention provides liquid dosage forms for treating narcolepsy. The liquid dosage form includes zolpidem or a pharmaceutically acceptable salt thereof, a carbonate salt, a metal oxide, and a borate salt.

08/01/13
20130196994 

Pde10 inhibitors and related compositions and methods


Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.

07/18/13
20130184298 

Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators


The present invention is directed to dihydrobenzoquinazilinone compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

07/18/13
20130184286 

Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors


This invention is related to the alkyl-piperazine-phenyl 4 (3h)-quinazolinones general formula (i) compounds, pharmacologically active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors..

06/13/13
20130150434 

Methods of using low-dose doxepin for the improvement of sleep


Methods of treating sleep disorders by administration of low doses of doxepin in individuals seeking sustained efficacy or in need of avoiding weight gain, rebound insomnia, or sedative tolerance resulting from doxepin treatment.. .

06/06/13
20130143965 

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy


Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into gbl.

06/06/13
20130143912 

Sublingual zolpidem formulations


The present disclosure provides pharmaceutical compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the compositions devoid of buffer and in the presence of alkaline oxides capable of raising the ph of saliva to a ph greater than about 7.0 thereby facilitate the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form.

06/06/13
20130143868 

Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders


The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of dopa decarboxylase inhibiting compounds, catechol-o-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof.



Sleep Disorders topics: Sleep Disorder, Sleep Disorders, Narcolepsy, Schizophrenia, Antagonist, Pyrazole Derivatives, Movement Disorder, Movement Disorders, Eating Disorder, Eating Disorders, Neurological, Pharmaceutically Acceptable Salt, Intracranial, Opiate Withdrawal, Growth Hormone

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Sleep Disorders for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sleep Disorders with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.0539

5254

1 - 1 - 103